Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Tinea Pedis, Athlete's Foot
Interventions: Econazole Nitrate Foam 1%, Vehicle Foam; Drug · Other
Lead sponsor: AmDerma; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Miramar, Florida • Clinton Township, Michigan • Las Vegas, Nevada + 4 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mRNA-2736; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Miami, Florida • St Louis, Missouri + 7 more

Conditions: Multiple Sclerosis, Relapse
Interventions: Blood samples and processing; Diagnostic Test
Lead sponsor: Regina Elena Cancer Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Disease of Cardiovascular System, Multiple Chronic Conditions, Chronic Disease
Interventions: MOCHA; Behavioral
Lead sponsor: University of Massachusetts, Amherst; Other
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Amherst, Massachusetts • Springfield, Massachusetts

Conditions: Obesity and Overweight
Interventions: MET097, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Scottsdale, Arizona • Canoga Park, California • Oxnard, California + 33 more

Conditions: Opioid-Induced Bowel Dysfunction
Interventions: Lubiprostone 24; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 120
States / cities: Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more

Conditions: MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Resmetirom; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Spasticity, Multiple Sclerosis
Interventions: IPX056, Baclofen IR, Placebo IPX056, Placebo IR; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Tucson, Arizona • Aurora, Colorado • Tampa, Florida + 8 more

Conditions: Androgenetic Alopecia
Interventions: 5% Minoxidil Topical Foam, Vehicle Topical Foam; Drug
Lead sponsor: Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more

Conditions: Microbiota
Interventions: OTC Eczema Moisturizer Regimen, Cosmetic Moisturizer Regimen; Drug · Other
Lead sponsor: Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.; Industry
Eligibility: 16 Years to 50 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Richardson, Texas

Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma
Interventions: Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation, Fludarabine, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Thiotepa; Drug · Procedure · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2024
U.S. locations: 3
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Atrial Fibrillation
Interventions: Aegis Sierra Ligation System; Device
Lead sponsor: Aegis Medical Innovations; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 4
States / cities: Santa Monica, California • Rochester, Minnesota • New York, New York + 1 more

Conditions: Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib, sorafenib tosylate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Overweight, Obesity
Interventions: NNC0247-0829, Placebo (NNC0247-0829); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
Interventions: LAVA-051, Interleukin 2; Biological
Lead sponsor: Lava Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 2 more

Conditions: Dysarthria, Down Syndrome
Interventions: Speech sessions; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 8 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypercatabolic Status Related to Severe Burn
Interventions: BVS857, placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Kidney Disease
Interventions: Zemplar Capsule; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 16
States / cities: San Diego, California • Washington D.C., District of Columbia • Fort Meyers, Florida + 12 more

Conditions: Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
Interventions: MyoCell™ Autologous Myoblasts; Drug
Lead sponsor: Bioheart, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Multiple Sclerosis, Pain, Depression
Interventions: Collaborative Care (CC); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation; Genetic · Radiation
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 10
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 19
States / cities: Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg, BFF MDI 320/9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 8,588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 318
States / cities: Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 249 more

Conditions: Chronic Pain
Interventions: Music Therapy; Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis

MOCHA Moving Forward: a CBPR Investigation of Chronic Disease Prevention in Older, Low-income African-American Men

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

Study of Resmetirom in Children and Adolescents With MASH

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Clinical Trial in Females for Female Pattern Hair Loss

Clinical Trial to Assess the Effects of Topical Lotions on Changes in the Skin Microbiome and Associations With Itch

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Intensive Dysarthria Sessions in Adults and Children With Down Syndrome

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection

Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study

MAGE-A4ᶜ¹º³²T for Multi-Tumor

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

POP SINGER Pilot Study